- Market Research
- Biologics Contract Manufacturing Demand Market Segmented By Monoclonal Antibodies, Vaccines, Growth Factors, Interferons, Recombinant Hormones, Insulin Product with Mammalian, Microbial Platform in Clinical, Commercial Application in Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders Therapeutic Area
Leading industry players are focusing on the development and launching of next-generation biotherapeutics to treat serious life-threatening diseases, which is expected to propel biologics contract manufacturing demand. The number of biotech patents applied for has been growing at approximately 23% annually.
Currently, over 1,500 biomolecules have been undergoing clinical trials, which are targeting several types of diseases. The expected success rate of biologics has so far doubled as compared to small molecule products, which is pushing biologics contract manufacturing demand. For instance, according to the IMS Institute for Healthcare Informatics, over US$ 57 billion biologic sales will be off-patent per year by 2020.
Global biologics contract manufacturing demand is anticipated to reach 8 Mn liters (MnL) by the end of 2030. Biopharmaceuticals contract development and manufacturing (CDMO) services are expected to grow at a double-digit growth rate, owing to a huge pipeline of therapeutics and the COVID-19 pandemic, with limited capability of biopharmaceutical contract development and manufacturing organizations (CDMOs), and is expected to exhibit a CAGR of 20% during the forecast period (2020-2030).
Find Out More about the Report Coverage
- BioXcellence (Boehringer Ingelheim GmbH)
- Lonza Group AG
- Samsung Biologics Co. Ltd.
- Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
- AbbVie Contract Manufacturing (AbbVie Inc.)
- WuXi Biologics (Cayman) Inc.
- Patheon N.V. (Thermo Fisher Scientific Inc.)
- Emergent BioSolutions Inc.
- AGC Biologics
- Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
- Avid Bioservices, Inc.
- KBI Biopharma (JSR Life Sciences (JLS))
- Catalent Inc.
- Abzena Plc.
Monoclonal Antibodies Dominating Biologics Contract Manufacturing Demand
The favorable safety profile of monoclonal antibodies associated with therapeutic use and high specificity constitutes it as the largest class of biologics in the North America biopharmaceuticals contract research, development, and manufacturing industry. Increasing demand for antibody-based therapeutics is expected to drive biologics contract manufacturing demand, followed by recombinant proteins, and vaccines.
Advanced variants of monoclonal antibodies such as antibody fragment-based products and bispecific antibodies are also steadily gaining traction in the pharmaceutical industry, which is expected to boost biologics contract manufacturing demand over forecast period.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Large Variations in Pricing: On-time Biologics Contract Manufacturing Demand Slots and Quality Outweigh Price in Decision Making
There have been a large variation of the price quotation by CDMOs per batches of biopharmaceuticals drug substance manufacturing. Significant set of factors that fluctuates prices per batch with higher lead time for slots availability includes scale of manufacturing, nature of therapeutic biopharmaceutical, bio production platform used, nature of CDMO, location of facilities, and nature of the targeted client. From a long-term perspective, there is expected 5% annual reduction in prices per batch, owing to the rise in well-established CDMOs and new entrants in the industry.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
High Consolidation Activities by Biologics Contract Manufacturing Players Creating Strong Growth Opportunities
Global biologics contract manufacturing demand will also see more consolidation as key players look to inorganic growth strategies to offer integrated solutions to customers. Companies interested in global biologics contract manufacturing demand are seeking to consolidate their position through acquisitions, collaborations, and partnerships with small and medium manufacturers in the market, and expand their product reach. Consolidation activities significantly accelerate a company's strategy and builds scale and depth in biologics contract manufacturing demand services.
For instance, in July 2020, Lonza Group AG acquired Shire plc. for the lucrative growth of its mammalian manufacturing business.
Explore Persistence Market Research’s expertise in promulgation of the business !
Key players related to biologics contract manufacturing demand covered in this report are BioXcellence (Boezhringer Ingelheim), Lonza Group AG, Fujifilm Diosynth, AbbVie CM, Catalent Inc., Therapure Biopharma Inc., Patheon N.V., Emergent BioSolutions Inc., Ajinomoto Bio-Pharma, Merck KGaA, Avid Bioservices, Inc., among others.
To meet biologics contract manufacturing demand, these key players are entering into strategic collaborations with partners to maintain market leadership across different regions. They are also engaging in exapansion of their manufacturing capacities in order to maintain a strong foothold over the forecast period.
COVID-19 Crisis Impact on Biologics Contract Manufacturing Demand
There has been high allocation of funding from local governments and companies for the expansion of existing facilities and construction of new facilities to tackle the COVID-19 pandemic. In addition, enhancing unique vaccine CDMO capabilities and capacity with technological advancements is the core strategy followed by leading CDMO players.
For example, in June 2020, Emergent BioSolutions Inc. joined the U.S. Government’s Warp Speed Program in a landmark public-private CDMO partnership for rapid COVID-19 vaccine domestic development and manufacturing through 2021, valued at approximately US$ 628 million.
A comprehensive perspective of biologics contract manufacturing demand has led our analysts to infer that, the industry is growing at a remarkable rate, with Europe and North America leading in biologics contract manufacturing demand. Global increase in the patient pool suffering from lifestyle and chronic diseases and COVID-19 vaccine need around the world have created huge short-term demand for biologics contract manufacturing.
However, growing emphasis of biopharmaceutical companies to reduce their product cost is also expected to gain traction in the long term as far as biologics contract manufacturing demand is concerned.
Key Segments of Biologics Contract Manufacturing Demand
PMR’s study on biologics contract manufacturing demand offers information divided into five important segments— product, platform, application, therapeutic area, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.